ASK REDCHAT ANYTHING ABOUT KAZIA THERAPEUTICS LIMITED
Kazia Therapeutics Limited (NASDAQ: KZIA)
Listen to this Section
$13.42
-0.1400
(
-1.03% )
237.5K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| Paxalisib (GDC-0084) (PI3K pathway)DetailsGlioblastoma |
Phase 2/3 |
| Paxalisib (GDC-0084) (PI3K pathway)DetailsGlioma |
Phase 2 |
| Paxalisib (GDC-0084) (PI3K pathway)Detailsprimary central nervous system lymphomas |
Phase 2 |
| EVT801DetailsSolid tumor/s, Cancer |
Phase 2 |
| Cantrixil (TRX-E-002-1)DetailsOvarian cancer |
Failed |
| Paxalisib (GDC-0084)DetailsGlioblastoma |
Phase 2/3 |
| Paxalisib (GDC-0084)DetailsGlioma |
Phase 2 |
| Paxalisib (GDC-0084)Detailsprimary central nervous system lymphomas |
Phase 2 |
Market Data
|
| Open |
$13.42 |
| Previous Close |
$13.56 |
| Volume |
237.5K |
| Market Cap |
$154.95M |
| Day Range |
$11.99 - $13.62 |
| 52 Week Range |
$4.86 - $17.40 |
| Shares Outstanding |
11.43M |
| Change % |
-1.03% |
| Net Change |
▼ -0.1400 |
| Insider Ownership |
N/A |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations |
| IPO Year | 1999 |
| Country | Australia |
Insider Ownership Transactions
Total Amount Purchased:
0.00
| Date |
Type |
Amount Purchased |
Purchaser |
| No records found. |